PMID- 35815265
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221209
IS  - 1741-427X (Print)
IS  - 1741-4288 (Electronic)
IS  - 1741-427X (Linking)
VI  - 2022
DP  - 2022
TI  - Effects of Tenofovir Combined with Recombinant Human Interferon alpha-2b on Negative 
      Conversion Rate, Liver Function, Immune Status, and Drug Safety in Patients with 
      Chronic Hepatitis B: A Systematic Review and Meta-Analysis.
PG  - 1889628
LID - 10.1155/2022/1889628 [doi]
LID - 1889628
AB  - OBJECTIVE: To systematically evaluate the clinical value of tenofovir combined 
      with recombinant human interferon alpha-2b in the treatment of chronic hepatitis B 
      and to provide evidence-based medicine for its popularization and use. METHODS: 
      The randomized controlled trials (RCTs) of tenofovir combined with recombinant 
      human interferon alpha-2b in the online database of PubMed, EMBASE, ScienceDirect, 
      Cochrane Library, China knowledge Network (CNKI), China VIP database, Wanfang 
      database, and China Biomedical Literature Database (CBM) were searched. The data 
      included in this study were extracted by two independent researchers. After 
      extracting the data of the study, the Cochrane manual 5.1.0 standard was used to 
      evaluate the bias risk of all the literature included in this study. RevMan5.4 
      statistical software was used to analyze the collected data by meta. RESULTS: 
      Entecavir combined with recombinant human interferon alpha-2b can inhibit the 
      activity of HBV polymerase and improve the inflammatory response of the liver. 
      Recombinant human interferon alpha-2b can regulate immune function by inducing T cell 
      differentiation and maturation and enhancing the production of cytokines. The 
      systematic evaluation showed that entecavir combined with recombinant human 
      interferon alpha-2b had higher serum HBeAg negative conversion rate, higher drug 
      safety compared with entecavir alone, and improved liver function and immune 
      status. CONCLUSION: Tenofovir combined with recombinant human interferon alpha-2b 
      has a high serum HBeAg negative rate and safety profile for the treatment of 
      chronic hepatitis B. The combination treatment can improve liver function and 
      immune status in patients, but more studies with higher methodological quality 
      and longer duration of intervention are needed for further validation.
CI  - Copyright (c) 2022 Hui Zhang et al.
FAU - Zhang, Hui
AU  - Zhang H
AD  - The Medical Department of Hepatology, Jiangsu Taizhou People's Hospital, Taizhou 
      225300, China.
FAU - Xian, Jianchun
AU  - Xian J
AD  - The Medical Department of Hepatology, Jiangsu Taizhou People's Hospital, Taizhou 
      225300, China.
FAU - Li, Yang
AU  - Li Y
AD  - The Medical Department of Hepatology, Jiangsu Taizhou People's Hospital, Taizhou 
      225300, China.
FAU - Xiao, Li
AU  - Xiao L
AD  - The Medical Department of Hepatology, Jiangsu Taizhou People's Hospital, Taizhou 
      225300, China.
FAU - Wang, Lu
AU  - Wang L
AUID- ORCID: 0000-0002-1266-7916
AD  - The Medical Department of Neurology, Jiangsu Taizhou People's Hospital, Taizhou 
      225300, China.
LA  - eng
PT  - Journal Article
PT  - Retracted Publication
DEP - 20220630
PL  - United States
TA  - Evid Based Complement Alternat Med
JT  - Evidence-based complementary and alternative medicine : eCAM
JID - 101215021
RIN - Evid Based Complement Alternat Med. 2022 Nov 29;2022:9791408. PMID: 36482933
PMC - PMC9262527
COIS- The authors declare that they have no conflicts of interest.
EDAT- 2022/07/12 06:00
MHDA- 2022/07/12 06:01
CRDT- 2022/07/11 04:30
PHST- 2022/05/07 00:00 [received]
PHST- 2022/05/25 00:00 [revised]
PHST- 2022/05/29 00:00 [accepted]
PHST- 2022/07/11 04:30 [entrez]
PHST- 2022/07/12 06:00 [pubmed]
PHST- 2022/07/12 06:01 [medline]
AID - 10.1155/2022/1889628 [doi]
PST - epublish
SO  - Evid Based Complement Alternat Med. 2022 Jun 30;2022:1889628. doi: 
      10.1155/2022/1889628. eCollection 2022.